ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading

Author： Oparil Suzanne   Kjeldsen Sverre   Hedner Thomas   Narkiewicz Krzysztof  

Publisher： Informa Healthcare

ISSN： 0803-7051

Source： Blood Pressure, Vol.18, Iss.1-2, 2009-04, pp. : 4-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ONTARGET Trial Programme: Facts and Lessons

By  

Current Hypertension Reviews, Vol. 5, Iss. 3, 2009-08 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL

By Sander D.  

Der Internist, Vol. 50, Iss. 11, 2009-11 ,pp. : 1227-1238

Springer Publishing Company

Access to resources Recommend Favorite

The Myth of Janus: The Two Faces of Renal Outcomes in the ONTARGET Study

By Volpe Massimo  

High Blood Pressure & Cardiovascular Prevention, Vol. 16, Iss. 2, 2009-06 ,pp. : 35-37

Adis International

Access to resources Recommend Favorite

A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET

By Kjeldsen Sverre   Oparil Suzanne   Narkiewicz Krzysztof   Hedner Thomas  

Blood Pressure, Vol. 17, Iss. 2, 2008-01 ,pp. : 68-69

Informa Healthcare

Access to resources Recommend Favorite

Telmisartan and Stroke Reduction in the ONTARGET Trial: Benefit beyond Blood Pressure Lowering?

By  

Cerebrovascular Diseases, Vol. 26, Iss. 5, 2008-10 ,pp. : 563-564

Karger

Access to resources Recommend Favorite